帕利哌酮缓释片对精神分裂症的疗效及安全性分析

程亚玲　韩海斌

【摘 要】目的：探讨帕利哌酮缓释片对精神分裂症的疗效及安全性分析。方法：选择从2016年1月至2018年12月收治的100例精神分裂症患者为对象，采用随机数字表法分为2组，命名为对照组（50例）与研究组（50例）。对照组给予阿立哌唑口腔崩解片治疗，研究组给予帕利哌酮缓释片治疗，两组均持续治疗1个月。结果：研究组患者的临床治疗总有效率为92.00%，明显高于对照组的70.00%，差异有统计学意义（=7.8622，P<0.05）;研究组患者治疗前的PANSS评分与对照组比较，差异无统计学意义（t=0.0130，P>0.05）;研究组患者治疗后7dPANSS评分为（60.90±12.25）分，治疗后14dPANSS评分为（52.55±15.55）分，治疗后28dPANSS评分为（40.10±15.75）分，明显低于对照组的（69.85±12.10）分，（60.60±15.70）分，（49.60±13.70）分，差异有统计学意义（t=2.9560，2.0927，2.6143，P<0.05）;研究组患者的不良反应发生率为4.00%，明显低于对照组的20.00%，差异有统计学意义（=6.0606，P<0.05）。结论：对精神分裂症实施帕利哌酮缓释片治疗的疗效确切，且安全性高，值得推广应用。

【关键词】帕利哌酮缓释片;精神分裂症;疗效;安全性

Abstract：Objective investigate the efficacy and safety of paliperidone sustained-release tablets in schizophrenia.Methods One hundred patients with schizophrenia who were admitted from January 2016 to December 2018 were enrolled in the study.They were randomly divided into two groups and named as control group （50 cases） and study group （50 cases）.The control group was treated with aripiprazole orally disintegrating tablets， and the study group was given paliperidone sustained-release tablets.Both groups were treated for 1 month.Results The total effective rate of clinical treatment in the study group was 92.00%， which was significantly higher than that in the control group （70.00%）.The difference was statistically significant （2=7.8622， P<0.05）.The PANSS score of the study group before treatment was compared with the control group.The difference was not statistically significant （t=0.0130， P>0.05）.The PANSS score was （60.90±12.25） on the 7th day after treatment， and the PANSS score was （52.55±15.55） on the 14th day after treatment.The PANSS score was （40.10） on the 28th day after treatment.±15.75）， significantly lower than the control group （69.85±12.10）， （60.60±15.70）， （49.60±13.70）， the difference was statistically significant （t=2.9560， 2.0927， 2.6143， P<0.05） The incidence of adverse reactions in the study group was 4.00%， which was significantly lower than that in the control group （20.00%）， and the difference was statistically significant （2=6.0606， P<0.05）.Conclusion The efficacy of paliperidone sustained-release tablets in the treatment of schizophrenia is accurate and safe， and it is worthy of popularization and application.

【中圖分类号】R971.4【文献标识码】A【文章编号】1005-0019（2019）22-0-01

精神分裂症为临床常见的精神类疾病，该疾病具有慢性迁延、反复发作特点。目前临床治疗精神分裂症的基本原则为积极控制症状表现，以及积极控制阳性体征，从而降低病情复发率，以提高患者的社会功能，提高患者的生活质量。但是，由于精神分裂症患者的治疗依从性较差，而且中断药物治疗容易导致病情复发。因此，临床需加强重视[1-2]。本次研究工作旨在探讨帕利哌酮缓释片对精神分裂症的疗效及安全性分析。现报道如下。